Michelle Stecklein Call, CEO: Ms. Call has worked with entrepreneurial ventures for over a decade, initially as a partner in an early stage venture firm, Peninsula Equity Partners, and then as a member of the entrepreneurial endeavor itself. She built her business foundation as a senior management consultant at McKinsey & Company, as an investor in early stage technology companies and at Stanford University’s Graduate School of Business where she earned an MBA. She built her scientific foundation as an engineer and commercial development specialist at the Dow Chemical Company and at the Georgia Institute of Technology where she earned a Bachelor of Chemical Engineering.
Stephen F. Carroll, Ph.D., Director of Discovery & Development: Stephen F. Carroll, Ph.D., Director of Discovery & Development: Dr. Carroll leads Lypro’s preclinical programs. He comes to Lypro with substantive experience in advancing preclinical candidates to human trials. Dr. Carroll has drafted preclinical sections for over 12 INDs and 4 BLAs. He began his career at Harvard Medical School as an assistant professor of Microbiology & Molecular Genetics. He transitioned into industry to become a key member of Xoma, LLC, a leading biotechnology company specializing in the development of antibodies and recombinant proteins. At Xoma Dr. Carroll was the leader of all preclinical work.
Trudy M. Forte, Ph.D., Director of Research: Dr. Forte is an expert in lipoproteins and their role in human disease. Dr. Forte served as the Editor-in-Chief of the Journal of Lipid Research (1999-2003) and has held numerous distinguished roles with the American Heart Association. Prior to joining Lypro she was Senior Scientist at the Lawrence Berkeley National Laboratory where she pursued, amongst other ideas, nanoparticle therapeutics for the treatment of brain cancer (glioblastoma multiforme).
Robert O. Ryan, Ph.D., Founder, Board Member: Dr. Ryan is a renowned expert in lipids, lipoproteins, and lipid transport and metabolism. He is a Senior Scientist and Principal Investigator at Children’s Hospital of Oakland Research Institute (CHORI), a Adjunct Professor, Nutritional Sciences & Toxicology at University of California, Berkeley and has collaborated as a Visiting Professor at Stanford University School of Medicine, Department of Development Biology.
Bob Molinari, Ph.D., Board Member: Dr. Molinari is a serial entrepreneur in the life science arena. He has launched companies in the fields of biopharmaceutical research, proteomics, genomics and biotechnology reagents. Most recently he is the founding CEO of Retrotope, a company with drug candidates to mitigate diseases of oxidative degeneration. Dr. Molinari is an active investor and on the screening committee of the Life Science Angels. He serves on the board of directors of Lypro Biosciences, Allylix and PharmaSecure. Dr. Molinari began his early career at McKinsey & Company and Raychem Corporation. He holds a Ph.D. from Brown University where he was a Rufus Choate Scholar and an MBA from the Amos Tuck School of Business at Dartmouth.
Michael Oda, Ph.D., Founder: Dr. Oda is an expert in HDL structure-function. He is an Associate Scientist and Principal Investigator at CHORI. Dr. Oda is a co-inventor of multiple HDL-related patents, including NanoDisks. He has been an editorial board member of the Journal of Lipid Research, is the co-chair of the American Heart Association National grant review panel, and a standing member of the NIH Atherosclerosis and Inflammation of the Cardiovascular System Study Section.